Larger, multi-center studies of the correlation between CTNNB1 mutations in urine cfDNA and HCC tumor status are needed to evaluate the potential clinical utility of urinary CTNNB1 mutation detection in liver cancer management and precision medicine. Here, CTNNB1 is linked to neoplasm.